右半结肠癌完整结肠系膜切除与D3淋巴结清扫的系统综述
本系统综述评估右半结肠癌行完整结肠系膜切除(CME)与D3淋巴结清扫的术后结局、肿瘤复发和总生存。共纳入30项研究、5931例CME手术,汇总术后并发症1.88%、吻合口漏0.92%,5年总生存均值85%,肿瘤复发率12.25%。结论认为CME不增加术后并发症风险并显著改善长期肿瘤学结局。
要点
- CME汇总术后并发症1.88%、吻合口漏0.92%,不增加并发症风险。
- CME后5年总生存均值85%,I/II/III期分别为93.05%/89.76%/79.65%。
- CME后肿瘤复发率12.25%,5年复发I/II/III期分别为5.8%/7.68%/15.69%。
核心结论
- CME不增加术后并发症风险,并显著改善长期肿瘤学结局。
- 仍需前瞻性多中心研究验证CME能否成为右半结肠癌标准手术。
研究设计与样本
- 系统综述,遵循PRISMA标准,检索随机与非随机研究。
- 初检919项研究,110项全文审查,30项符合纳入标准。
- CME手术总例数为5931例。
主要发现
- 28项研究报告术后并发症,CME汇总总体并发症为1.88%。
- 6项研究报告总体术后并发症为0%。
- 27项研究报告吻合口漏,CME切除后汇总比例为0.92%。
- 16篇报告总生存,5年生存患者均值85%。
- 21项研究报告局部和远处复发,CME后肿瘤复发率为12.25%。
关键数值与推荐
- 5年总生存均值:I期93.05%,II期89.76%,III期79.65%。
- 5年肿瘤复发:I期5.8%,II期7.68%,III期15.69%。
临床怎么用
- 右半结肠癌行CME与D3淋巴结清扫时,可参考其不增加并发症且改善长期肿瘤学结局的证据。
局限性
- 纳入研究为随机与非随机研究,结论需前瞻性多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In right-sided colon cancer surgery, currently there is a great deal of discussion and debate regarding complete mesocolic excision (CME) versus conventional right hemicolectomy (CRH) on postoperative outcomes and oncological results. Our aim was to perform a systematic review of the short- and long-term outcomes of CME to standardize surgical approach in patients with right-sided colon cancer. METHODS: A systematic review was performed examining available data on randomized and non-randomized studies evaluating the role of CME and D3 lymphadenectomy in the treatment of right-sided colon cancer, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards. RESULTS: After literature search, 919 studies have been recorded, 110 studies underwent full-text reviews and 30 studies met inclusion criteria. The total number of CME procedures was 5931. Postoperative complications was reported in 28 studies with pooled overall complications of 1.88% for CME surgery. Six studies reported 0% of overall postoperative complications and they demonstrated a low incidence of complications following CME procedure. Anastomotic leak was reported in 27 studies with pooled proportion of 0.92% after CME resections. There were 16 papers reporting overall survival following CME procedure, with a mean of 85% of patients survived at 5 years. Mean 5-year overall survival was 93.05% in stage I patients, 89.76% in stage II patients and 79.65% in stage III patients. Local and distant recurrence were included in 21 studies, reporting tumor recurrence rate of 12.25% following CME. 5-year tumor recurrence was 5.8% in stage I patients, 7.68% in stage II patients and 15.69% in stage III patients. CONCLUSIONS: CME does not increase the risk of postoperative complications and significantly improves the long-term oncological impact. Prospective multicentre studies results are needed to verify if CME could be considered standard surgery for right colon cancer.
引用
- Mazzarella G, Muttillo EM, Picardi B, et al. Complete mesocolic excision and D3 lymphadenectomy with central vascular ligation in right-sided colon cancer: a systematic review of postoperative outcomes, tumor recurrence and overall survival. Surg Endosc. 2021. PMID: 33977376. doi:10.1007/s00464-021-08529-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。